Clinical Trial

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Study acronym: CURB2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.
Protocol Amendment History 3 changes
notable Trial sites expanded: 64 -> 74 locations 2026-06-10
notable Trial sites expanded: 57 -> 64 locations 2026-05-13
notable Trial sites expanded: 49 -> 57 locations 2026-04-15
Trial Details
NCT Number NCT06686771
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, NRG Oncology, SWOG Cancer Research Network
Conditions Non-small Cell Lung Cancer
Enrollment 320 participants
Start Date 2025-12-16
Primary Completion 2030-02-28 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-14